Frontlight ResearchEarly access
Taking peoplePhase 4
Alfacalcidol for high parathyroid hormone after gastric bypass surgery
Tests alfacalcidol for secondary hyperparathyroidism in adults after gastric bypass surgery.
Key facts
- Who runs it
- Academisch Ziekenhuis Leiden
- Where
- Netherlands5 sites in 1 countryChoose a country to see its sites
- Registry title
- Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial (ActiVitD)
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 130 people, planned
- Started
- 4 Nov 2024
- Planned end
- 1 May 2026
- Type of study
- Interventional
- Record updated
- 4 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults who had Roux-en-Y gastric bypass surgery and now have secondary hyperparathyroidism. This means the parathyroid glands make too much hormone. The trial tests alfacalcidol, a form of active vitamin D.
- Age
- 18 years or older
- Sex
- Men and women, both before and after menopause
- Disease stage
- Secondary hyperparathyroidism that started after Roux-en-Y gastric bypass surgery
- Earlier treatment
- Must have had Roux-en-Y gastric bypass surgery. Must be taking only standard supplements. People already on active treatment for osteoporosis cannot join.
- Biomarker or test result
- Vitamin D level must be sufficient (>50 nmol/l)
Main reasons for not taking part
- Chronic kidney disease with eGFR < 60 ml/min
- A second weight-loss operation after an earlier one
- Long-term steroid use, or known inflammatory conditions such as rheumatoid arthritis
- High calcium in the blood at screening
- Active wish to become pregnant
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Men and both pre- and postmenopausal women who have had Roux-en-Y-gastric bypass surgery, aged 18 years or above, and present with secondary hyperparathyroidism after surgery, with a vitamin D sufficient state (>50 nmol/l), and only on standard supplementation, are included
- Provide informed consent prior to any specific study procedure
Who cannot take part
- Patients that are on chronic steroid use, for example for inflammatory conditions
- Patients with known inflammatory conditions (i.e. rheumatoid arthritis)
- Patients with chronic kidney disease defined as eGFR < 60 ml/min
- Patients who are already on active treatment for osteoporosis before inclusion
- Patients who had a bariatric intervention before and are re-operated
- Patients that appear to have hypercalcemia on screening
- Patients that have an active pregnancy wish
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To investigate the effect of alfacalcidol on the treatment of secondary hyperparathyroidism in patients after RYGB
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- Active vitamin D for secondary hyperparathyroidism after bariatric surgery: a multicenter randomized controlled trial (ActiVitD)
- Plain-language title
- Alfacalcidol for high parathyroid hormone after gastric bypass surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Record updated
- 4 November 2024